Eupraxia Pharmaceuticals Inc. Common Stock

Eupraxia Pharmaceuticals held its Annual General Meeting on June 18, 2026, where all seven board nominees were elected with strong shareholder support. The company also re-appointed KPMG LLP as auditor. Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release products using its proprietary Diffusphere™ technol...

Eupraxia Pharmaceuticals announced it will present 4 abstracts at Digestive Disease Week (May 2-5, 2026) showcasing clinical data from its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis. The presentations include an oral presentation on dose escalation leading to persistent histological improvements over 36 weeks, plus...

Eupraxia Pharmaceuticals announced positive 36-week data from the highest dose cohort (Cohort 9) of its Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis. The trial showed robust tissue health improvements with 90% reduction in EoEHSS Stage and 72% reduction in Peak Eosinophil Count, along with 66% clinical remission rat...

The US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP in...

Eupraxia Pharmaceuticals announced the closing of a $63.2 million public offering and reported Q4 2025 financial results. The company achieved clinical milestones with its lead program EP-104GI in eosinophilic esophagitis, demonstrating positive tissue health data. Cash reserves increased to $80.5 million, with runway extending into the second ha...